Procedures
toxicity, intercurrent illness
DISEASE PROGRESSION
All patients received TQB2858 (1800 mg) once every 3 weeks, which was delivered as a 20-min to 1-h intravenous infusion. Doses were reduced or delayed in subsequent cycles for certain patients, depending on toxicity. Intrapatient dose escalation was not permitted. Treatment was continued until any of the following occurred: disease progression, an intercurrent illness that prevented additional treatment, a treatment delay of greater than 3 weeks for any reason, unacceptable adverse event(s), general or specific changes in the patient’s condition that rendered additional treatment unacceptable (as judged by the investigator), or withdrawal of patient consent.